Clinical guideline: management of the first unprovoked epileptic seizure in adults and children

José A. Gien-López1, Raymundo A. Cueva-Escalante2, Enrique García-Cuevas3, María R. Márquez-Estudillo4, Blanca E. Villaseñor-Anguiano5, Raúl Leal-Cantú6 and Ramón E. Jiménez-Arredondo7

1Hospital Regional No. 1. IMSS, Mérida, Yucatán; 2Hospital Infantil de Tlaxcala, Tlaxcala; 3Hospital General Acapulco Guerrero; 4Hospital Regional de Puebla, ISSSTE, Puebla; 5Hospital General de Zona No. 1. Colima, Colima; 6Hospital Civil “Dr. Miguel Silva”, Morelia, Michoacán; 7Hospital General de Zona No. 1. “Luis Ernesto Miramontes Cárdenas”, IMSS Tepic, Nayarit, Mexico City, Mexico.

Abstract

Unprovoked seizures represent a challenge in the neurological clinical consult. Identifying a first unprovoked seizure is the first step for an adequate medical approach, for which there are different diagnostic tools that help establish the risk of a second seizure, as well as recurrence factors for a first unprovoked epileptic seizure (UES) or diagnose epilepsy. Pharmacological treatment for a first UES and key points for referral to specialists are similarly established, and we move forward to the reference for the next level of medical attention. In this section we also describe nonmedical recommendation for patients and family members after a first UES. A Mexican Guideline was elaborated accounting for the resources and diagnostic tools available in both public and private hospitals in Mexico.

Key words: Epilepsy. Unprovoked. Guidelines.

Introduction

This guideline was developed based on research questions under the PICO method, where questions are presented with their corresponding answer, establishing levels of evidence to offer specific orientation regarding the international recommendations on the related subject matter, seeking the exposure and application of these same management criteria for first unprovoked seizures in children and adults. The final objective of this guide is to aid health-care professionals in solving the initial questions when faced with a patient who has suffered an epileptic seizure (ES) and to make decisions based on the best evidence available.

1. What are the characteristics of acute symptomatic ESs and unprovoked ESs (UES)?

An acute symptomatic ES, provoked or reactive, can be defined as seizures presented during the course of a disease which temporarily lowers the threshold of an ES; this type of seizure is not considered epilepsy1.
For the condition to be considered a provoked ES, the required time span between a cerebral injury and onset of the seizure is 7 days for injuries such as traumatic brain injury (TBI), brain surgery, cerebrovascular disease, and cerebral anoxia and for the acute phase of infections of the central nervous system (CNS); 24 h for patients with metabolic disorders; and 7-48 h after the last ingestion of alcohol in patients with abstinence2.

An UES is characterized by the lack of temporary or reversible risk factors that lower the threshold to present an ES3. The diagnosis of an ES and epilepsy is based on the patient's medical history, the information obtained during direct questioning when the patient's consciousness is preserved and is able to describe the obtained during direct questioning when the patient's medical history, the information obtained from a first-hand witness of the seizure. A thorough medical history must be obtained to allow the clinician to identify if the event is an ES as well as the type of seizure. This information will also be useful to establish a differential diagnosis between an ES and non-ES such as Psychogenic, syncope or migraine, among other causes4. The medical history has always been considered the cornerstone of the approach to any disease, and patients with ES and epilepsy are not the exception5.

2. What are the precipitating risk factors after a first UES?

A systematic review published in 2015, consisting of 10 randomized control studies, revealed that treatment versus lack of treatment of first ES resulted in early recurrence within 2 years from 21% to 45% in the 1st year, respectively6. Certain clinical characteristics can determine seizure recurrence. This study demonstrated that the majority of patients with UES are between 16 and 60 years of age, which implies that the age groups before and after this age range have a greater recurrence risk of 2.1 (95% confidence interval = 1.0-4.3). Other risk factors for seizure recurrence include positive family history, history of febrile seizures, first prolonged seizure, initial suspicion of epilepsy, unknown epilepsy etiology, abnormal physical examination, and nocturnal seizures in patients aged 1-4 years when compared to patients who remain awake during seizures7. A paroxysmal electroencephalogram (EEG), structural injury visible on magnetic resonance imaging (MRI), and prolactin levels are highly specific, yet a poorly sensitive test for ES. Prolactin levels over 36 ng/mL are highly suggestive of ES; however, these must be measured between 20 min and 4 h from the onset of the seizure8. A lumbar puncture is useful when neuroinfection is suspected9.

### Evidence

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Level</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain injury, epileptiform EEG pattern, abnormal brain imaging, and nocturnal crisis are factors that increase the degree of recurrence and aid in the decision to initiate treatment</td>
<td>1</td>
<td>A</td>
</tr>
</tbody>
</table>

3. Which diagnostic tests are useful for the diagnosis and prognosis of a first UES?

**EEG** – evidence demonstrates that all patients with a first UES should be submitted to an EEG because the data obtained are useful for diagnosing ES when abnormalities are present. Determining the type of ES also helps in identifying the etiology in some cases, and establishing a differential diagnosis from NES8. EEG data are also useful in the selection of the anti-epileptic drugs (AED), whenever these are medically indicated. It must be noted, however, that abnormal EEG results without clinical manifestations are not considered epilepsy, and conversely, patients with epilepsy may have a normal EEG9.

A meta-analysis of 16 studies established as a seizure recurrence indicator for an UES epileptiform discharges on the EEG (2.0; CI 95%: 1.6-2.6). If the EEG showed non-epileptiform discharges, there was a recurrence of seizures; however, no statistical significance was found10. Records of brain electrical activity within the first 24 h after the first UES increase the probability of detecting interictal epileptiform discharges (IEDs). The IED is most frequently recorded among temporal epilepsies when compared to extratemporal epilepsies11, and they increase seizure recurrence risk.

The EEG must be carried out and interpreted by certified personnel, on patients under hyperventilation and with at least 20 min of recorded patterns without artifacts. Current guidelines suggest that an EEG is a necessary test for the evaluation and treatment determination after a first ES6. EEGs are the most common test used for diagnosing epilepsy. An epileptiform discharge on an EEG was associated with a relative increase in the recurrence rate of ESs when compared to a normal EEG12. Patients with an abnormal EEG with epileptiform discharges presented a recurrence risk of 60% after a first seizure. According to the ILAE 2017, 60% recurrence risk mandates that the first seizure should be considered epilepsy. The probability of
finding an abnormality on the EEG is higher after repeat studies, where 39% of patients presented abnormalities on the first test and 68% on their third test. Patients with epileptiform discharges have a 77% recurrence rate on a first UES compared to 47% if the EEG is normal. These discharges are better detected if the EEG is performed within the first 12 h after an ES. According to the ILAE, the recommended window to perform an EEG is within the first 72 h after a UES and within the first 24 h after an ES. If EEG results are normal, it is recommended to perform EEG tests during sleep, with sleep deprivation, photostimulation, and repeated tests. An unaltered routine EEG does not exclude the presence of an ES. Other studies report that an EEG performed within the first 6 h after an ES reveals the presence of epileptiform discharges in 67% of cases, between 6-12 h in 52%, 12-24 h in 24%, 24-48 h in 25%, 48-72 h in 22%, and 72-96 h in 18%. Based on the previous data, it can be concluded that prompt EEG tests after onset of seizures are more likely to detect epileptiform discharges and their efficacy of detection is progressively reduced in later tests. The American Academy of Neurology (AAN) in 2007 established a timeframe for EEGs within a window of 48 h after ES onset and up to an average of 15 days afterward.

EEG results from sleep-deprived patients improve the sensibility and specificity of the epilepsy diagnosis. Sleep induced by sleep deprivation is more likely to provoke epileptiform discharges when compared to physiological sleep. Seizure recurrence after a first ES with epileptiform discharges recorded on an EEG was 73.2%, whereas a normal EEG was associated with a 32.8% recurrence; thus, EEG records with epileptiform graphic patterns were established as a recurrence factor. Seizure recurrence on patients with generalized compared to focal epileptiform discharges was 68.8% and 75%, respectively. The recommendations of the AAN and the American Epilepsy Society (AES) for patients with a first UES and an EEG with epileptiform discharges are level A.

**Neuroimaging**

A computed tomography scan (CT) of the skull is performed in emergency cases on a patient with a first ES; its primary indication is to determine the presence of brain injuries that could cause an ES, such as a stroke or TBI. A CT may also be performed when physical exploration demonstrates a focal neurological deficit, a prolonged altered state of alertness and in febrile patients or with findings that suggest a CNS infection. MRIs detect more SNC alterations when compared to CT scan; thus, without a need for an emergency image, MRI is the technique of choice. Neuroimaging tests are necessary to predict the probability of recurrence after the first UES. They are indicated with the objective of identifying the etiology of the ES. The advantages of a CT are availability and the speed in which the test is performed, and the results obtained can guide the decision for the need of immediate medical attention, especially in emergency care. Neuroimaging tests have an important value in patients with epilepsy; research shows recurrence rates a year after the first seizure of 59% (95% CI 54-65%) if patients had an epileptogenic lesion visible on a CT or MRI and 44% (95% CI 41-48%) in patients without evident lesions by neuroimaging (p=0.001).

The recurrence rate of UES within 1 year in patients that demonstrated an epileptogenic lesion only by MRI was 67% compared to 50% for patients without a visible lesion. The MRI is superior to the CT in detecting epileptogenic abnormalities. If available, an MRI is the preferred neuroimaging technique in patients with a first UES. Neuroimaging tests should be performed following epilepsy protocol and interpreted by neuroradiology specialists.

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Children or adults with a first UES should undergo a thorough medical history and examination, followed by at least two diagnostic tests: neuroimaging (CT/MRI) and EEG</td>
<td>Class I C.II</td>
</tr>
<tr>
<td>A standard EEG is a useful study for the diagnosis of a first UES</td>
<td>Class III</td>
</tr>
<tr>
<td>An EEG with epileptogenic discharges is the best predictor for recurrence of a first UES, together with an abnormal neurological examination and corresponding etiology</td>
<td>Class I</td>
</tr>
<tr>
<td>An EEG helps to differentiate between an ES and other events of non-epileptic origin</td>
<td>Class I6</td>
</tr>
<tr>
<td>A routine EEG does not demonstrate evidence of brain abnormalities. A prolonged EEG is useful for the diagnosis of a first UES</td>
<td>Class II4</td>
</tr>
<tr>
<td>The VEEG is a useful test for the diagnosis of a first UES; it predicts a seizure recurrence of 46% in 12 months and 51% in 24 months</td>
<td>Class III4</td>
</tr>
<tr>
<td>The CT is a useful test for the diagnosis of a first UES</td>
<td>Class I6</td>
</tr>
</tbody>
</table>
4. What are recurrence factors for first UESs?

The AAN has described four factors that result in greater seizure recurrence: (1) an EEG with epileptiform abnormalities, (2) cerebral injury such as stroke or TBI, (3) a newly found lesion on neuroimaging, and (4) nocturnal seizures. After a patient suffers a second seizure, the patient has 60% of recurrence within the 1st year and 70% recurrence within the 2nd year.

If the seizure is of genetic etiology and the patient has a sibling with seizures, the recurrence risk is 29%. If the seizure is idiopathic with a spike and wave pattern on EEG, the risk increases to 50%. In children, a 5-year recurrence risk from the first seizure is 43%. In the presence of abnormalities on the EEG, the risk increases to over 50%, up to 65%.

An adult with epileptiform discharges on a routine EEG after a UES has 77% probability of a second seizure, while in children the probability is 66%. Children who present a seizure during sleep have a 75% probability of recurrence within 2 years compared to 49% in children who did not.

5. What are the indications for pharmacological treatment?

Currently, the decision whether to treat a first UES is a matter of controversy. It is generally accepted that AEDs are indicated as of the second UES because recurrence risk is greater (57% within the 1st year and 73% within 4 years). A study performed by the AAN and the AES based on 10 level A trials determined that the seizure recurrence risk of an adult with a first UES was between 21% and 45% within the first 2 years, and the cumulative risk of a second ES was 32% after a year and 46% for 5 years. In the Multicenter Epilepsy and Single Seizures (MESS) study, it was concluded that the recurrence of a first UES was 39% within 2 years and 51% within 5 years.

The probability of presenting an isolated ES is 8-10% and 3% of developing epilepsy, revealing an incidence rate of 61/100,000 individuals per year, resulting in a prediction that an estimated 4 million individuals each year will experience a first UES that may be focal or generalized, because 30% of paroxysmal episodes are inappropriately diagnosed.

To initiate treatment, it is important to confirm the presence of a first UES as there is no doubt that a simulator event is occurring. The degree of certainty of the diagnosis lies in an adequate interrogation, as well as physical and neurological examination, directed diagnostic tests, emphasizing important points of seizure semiology, suspicion of ES or epilepsy establishing a proper differential diagnosis, distinguishing between provoked ES and UES using the definition criteria for epilepsy, and investigating and classifying the type of seizure, as well as the recurrence risk. Treatment should be limited to observation and complementary tests if recurrence risk is low. AED should be initiated if the risk if moderate or high. If patients...
have an ES while being alone, complementary laboratory and other diagnostic tests such as the EEG must be performed as soon as possible, because its usefulness is greater in the first 24 h after the seizure. If epilepsy debut is suspected in subclinical seizures, it must be noted that <50% of seizures are detected by a 30-min routine EEG; however, this detection rate is increased to 90% if constant monitoring of 24-36 h is performed. Within the emergency care department, the accepted initial test is a CT, considering a subsequence risk when the risk is low. The accepted initial test is a CT, considering an increased risk of relapse but not the long-term prognosis, which must be noted that <50% of seizures are detected by a 30-min routine EEG; however, this detection rate is increased to 90% if constant monitoring of 24-36 h is performed. Within the emergency care department, the accepted initial test is a CT, considering a subsequent MRI, except if the CT demonstrates an important pathology or if the patient must be sedated.

Other tests, such as serum prolactin, are not recommended for the diagnosis of epilepsy; however, it is important to quantify serum electrolytes and glucose to identify potential causes or any comorbidities. An electrocardiogram or referral to a cardiologist must be performed in cases of a doubtful diagnosis. Neuropsychological evaluation is indicated when the MRI demonstrates important alterations or declines in the cognitive areas of the brain. To initiate treatment, the level of certainty of the diagnosis, the degree of alteration in the neurological examination, family history, laboratory and imaging test results, electroencephalography, the side effects of the AED indicated for the type of seizure, quality of life, and cost of treatment must be considered.

The treatment of the first UES reduces short-term recurrence risk but not the long-term prognosis. Thus, it is important to counterweigh AED side effects on recurrence risk when the risk is low, considering the possibility if recurrence is greater within the first 3-6 months.

<table>
<thead>
<tr>
<th>Evidence</th>
<th>Level</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial treatment should not be given after a first seizure except if the recurrence risk is high or under special circumstances</td>
<td>1</td>
<td>A</td>
</tr>
<tr>
<td>Pharmacological treatment should only be initiated after the diagnosis of epilepsy is confirmed</td>
<td>1</td>
<td>A</td>
</tr>
<tr>
<td>The decision to initiate treatment should be taken by the treating physician together with the patient or caregiver, after explaining the recurrence risk, side effects, and quality of life issues</td>
<td>1</td>
<td>B</td>
</tr>
<tr>
<td>The cornerstone of the diagnosis of an epileptic seizure is the clinical feature</td>
<td>1</td>
<td>B</td>
</tr>
<tr>
<td>The EEG is useful for the decision to initiate treatment</td>
<td>1</td>
<td>B</td>
</tr>
<tr>
<td>Neuroimaging tests, such as CT and MRI, are necessary evaluations of a patient with an isolated epileptic seizure</td>
<td>1</td>
<td>A</td>
</tr>
</tbody>
</table>

The treatment of the first unprovoked epileptic seizure reduces the risk of relapse but does not affect the long-term prognosis of epilepsy.

| CT/MRI: computed tomography/magnetic resonance imaging; EEG: electroencephalogram. |

6. What are the reference indications for a first UES?

Every patient with a first UES must be examined by a neurologist. According to the regional infrastructure, patients must be referred to a secondary or tertiary medical facility if there is any doubt about the type of provoked ES or if there is evidence of cerebral lesion whether it consists of a tumor, hemorrhage, or infection (cysticercosis, toxoplasmosis, or tuberculosis). Patients that debut with status epilepticus in their first ES must be referred to a specialized facility for treatment as soon as vital signs are stable. Approximately 6-7% of long debut seizures are considered as status epilepticus.

The etiology of a provoked ES was found to be stroke in 34.7%, TBI in 34.7%, and infection in the CNS in 30.6%. Conversely, etiology for first UES was a stroke in 68.2%, a TBI in 25%, and CNS infection in 6.8%.

It is important for patients to also undergo evaluation for seizure simulator conditions, where studies demonstrate that the most common simulator is a syncope reflex (74%) and psychogenic seizures (16%). The most common symptoms for reference to a secondary or tertiary medical facility are accompanying neurological manifestations, such as cephalgia, immediately after the seizure.

Mortality within the first 30 days from the first provoked ES was 21.4% (95% CI = 16.9-26.9%), compared to 3.4% for the first UES (95% CI = 1.4-7.9%, p < 0.001).

It has been suggested that in locations where a specialized neurological consult is unavailable, a remote consult by a specialist should be established by telephone or by video conference; this is a common occurrence in subspecialties such as pediatric neurology. Every referral to a tertiary health-care facility must include a complete medical history, specifying medication, semiology of neurological signs and symptoms that may aid in classifying the type of seizure, and the directed diagnostic evaluation.
Recommendations

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Every patient with a first epileptic seizure must be evaluated in a secondary health-care facility</td>
<td>R-PPE</td>
</tr>
</tbody>
</table>

Evidence

<table>
<thead>
<tr>
<th>Hospitalization criteria for patients with a first UES:</th>
<th>Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>− Under 1 year of age (afebrile)</td>
<td>Class III</td>
</tr>
<tr>
<td>− Atypical or complex epileptic crisis</td>
<td></td>
</tr>
<tr>
<td>− Prolonged postictal state</td>
<td></td>
</tr>
<tr>
<td>− Onset status epileptic</td>
<td></td>
</tr>
<tr>
<td>− Meningeal signs</td>
<td></td>
</tr>
<tr>
<td>− New neurological deficit (previously absent)</td>
<td></td>
</tr>
</tbody>
</table>

References

3. Guía de Práctica Clínica, Diagnóstico y Tratamiento de la Epilepsia en el Adulto en el Primer y Segundo Nivel de Atención, Actualización; 2015.
23. NICE Clinical Guideline 137, The Epilepsies: the Diagnosis and Management of the Epilepsies in Adults and Children in Primary and Secondary Care; 2012.